AstraZeneca recognised as a leader in 2016 Dow Jones Sustainability Indices (DJSI)

AstraZeneca has been named a sustainability leader within the Pharmaceuticals, Biotechnology and Life Sciences industry of the Dow Jones Sustainability Index (DJSI). The company’s score of 86% is an improvement of two points from 2015, and only three points behind the 2016 industry leader.

In addition, AstraZeneca again confirmed its spot in the top 10% of the largest 2500 companies (DJSE World Index), and in the top 20% of the 600 largest European companies (DJSI European Index) for the ninth consecutive year.

“We are incredibly proud of this recognition,” said Katarina Ageborg, AstraZeneca Chief Compliance Officer and responsible for co-ordinating Sustainability in the company. “Sustainability is embedded into everything we do here at AstraZeneca. We want to be valued and trusted by our stakeholders as a source of great medicines over the long term, which remains our most important contribution to sustainability. This requires us to operate in a way that recognises the interconnection between business growth, the broader needs of society, and the limitations of our planet.”

Inclusion in the DJSI is based on an in-depth analysis of economic, social and environmental performance, criteria and serve as benchmarks for investors who integrate sustainability considerations into their portfolios. Only the top ranked companies in terms of Corporate Sustainability within each industry are selected for inclusion in the Dow Jones Sustainability Index family.

In this year’s DJSI assessment, AstraZeneca made a significant improvement in the environmental dimension of this index, gaining 18 percentage points, and were awarded sector-best scores in Code of Conduct (100%), Marketing Practices (93%), Climate Strategy (100%), Occupational Health & Safety (88%) and Health Outcomes Contribution (100%).

In line with its commitment to environmental protection, in June this year AstraZeneca joined 64 of the world’s top companies to pledge a commitment to source 100% renewable electricity globally by 2025. Before then, the company has committed to an interim target of 100% in Europe and the US – which together account for three quarters of its electricity use – by 2020.

AstraZeneca was also recently awarded “Prime” status by Oekom Research during its annual rating process for corporate social responsibility.

AstraZeneca’s core commitments in sustainability include expanding access to healthcare, conducting research transparently and responsibly, and doing its fair share to conserve and protect natural resources.

For more information about AstraZeneca’s commitment to sustainability, click here.